Outcomes of Patients with Metastatic Renal Cell Carcinoma Treated with Targeted Therapy After Immuno-oncology Checkpoint Inhibitors

Jeffrey Graham,Amishi Y Shah,J Connor Wells,Rana R McKay,Ulka Vaishampayan,Aaron Hansen,Frede Donskov,Georg A Bjarnason,Benoit Beuselinck,Guillermo De Velasco,Marco Iafolla,Mei S Duh,Lynn Huynh,Rose Chang,Giovanni Zanotti,Krishnan Ramaswamy,Toni K Choueiri,Nizar M Tannir,Daniel Y C Heng

European Urology Oncology（2021）

引用 27|浏览24

暂无评分

摘要

Targeted therapy has clinical activity following immuno-oncology (IO) treatment. Patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor receptor tyrosine kinase inhibitors versus mammalian target of rapamycin inhibitors following IO therapy had improved clinical outcomes.

查看译文

关键词

Immuno-oncology,Metastatic renal cell carcinoma,Mammalian target of rapamycin inhibitors,Real-world effectiveness,Sequential therapies,Targeted therapy,Vascular endothelial growth factor receptor tyrosine kinase inhibitors

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要